首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >PELP1 Overexpression in the Mouse Mammary Gland Results in the Development of Hyperplasia and Carcinoma
【24h】

PELP1 Overexpression in the Mouse Mammary Gland Results in the Development of Hyperplasia and Carcinoma

机译:PELP1在小鼠乳腺中的过度表达导致增生和癌的发展

获取原文
获取原文并翻译 | 示例
           

摘要

Estrogen receptor (ER) coregulator overexpression promotes carcinogenesis and/ or progression of endocrine related-cancers in which steroid hormones are powerful mitogenic agents. Recent studies in our laboratory, as well as others, demonstrated that the estrogen receptor coregulator PELP1 is a proto-oncogene. PELP1 interactions with histone demethylase KDM1 play a critical role in its oncogenic functions and PELP1 is a prognostic indicator of decreased survival in patients with breast cancer. However, the in vivo significance of PELP1 deregulation during initiation and progression of breast cancer remains unknown. We generated an inducible, mammary gland-specific PELP1-expressing transgenic (Tg) mouse (MMTVrtTA-TetOPELP1). We found more proliferation, extensive side branching, and precocious differentiation in PELP1-overexpressing mammary glands than in control glands. Aged MMTVrtTA-TetOPELP1 Tg mice had hyperplasia and preneoplastic changes as early as 12 weeks, and ER-positive mammary tumors occurred at a latency of 14 to 16 months. Mechanistic studies revealed that PELP1 deregulation altered expression of a number of known ER target genes involved in cellular proliferation (cyclin D1, CDKs) and morphogenesis (EGFR, MMPs) and such changes facilitated altered mammary gland morphogenesis and tumor progression. Furthermore, PELP1 was hyper-phosphorylated at its CDK phosphorylation site, suggesting an autocrine loop involving the CDK-cyclin D1-PELP1 axis in promoting mammary tumorigenesis. Treatment of PELP1 Tg mice with a KDM1 inhibitor significantly reduced PELP1-driven hyperbranching, reversed alterations in cyclin D1 expression levels, and reduced CDK-driven PELP1 phosphorylation. These results further support the hypothesis that PELP1 deregulation has the potential to promote breast tumorigenesis in vivo and represent a novel model for future investigation into molecular mechanisms of PELP1-mediated tumorigenesis. (C) 2014 AACR.
机译:雌激素受体(ER)核心调节剂的过度表达可促进内分泌相关癌的癌变和/或进展,其中类固醇激素是强有力的促有丝分裂剂。我们实验室以及其他实验室的最新研究表明,雌激素受体共调节剂PELP1是原癌基因。 PELP1与组蛋白脱甲基酶KDM1的相互作用在其致癌功能中起关键作用,而PELP1是乳腺癌患者生存率降低的预后指标。然而,在乳腺癌的发生和发展过程中PELP1失活的体内意义仍然未知。我们生成了可诱导的,乳腺特异性的表达PELP1的转基因(Tg)小鼠(MMTVrtTA-TetOPELP1)。我们发现,与对照腺相比,PELP1过表达的乳腺有更多的增殖,广泛的侧支化和早熟分化。老年MMTVrtTA-TetOPELP1 Tg小鼠最早在12周时出现增生和肿瘤前变化,并且ER阳性乳腺肿瘤的发生时间为14至16个月。机理研究表明,PELP1失调改变了许多已知的ER靶基因的表达,这些靶基因参与细胞增殖(细胞周期蛋白D1,CDKs)和形态发生(EGFR,MMP),并且这种改变促进了乳腺形态发生和肿瘤进展的改变。此外,PELP1在其CDK磷酸化位点被过度磷酸化,表明涉及CDK-cyclin D1-PELP1轴的自分泌环可促进乳腺肿瘤的发生。用KDM1抑制剂治疗PELP1 Tg小鼠可显着减少PELP1驱动的超支化,细胞周期蛋白D1表达水平的逆向改变以及CDK驱动的PELP1磷酸化。这些结果进一步支持以下假设:PELP1放松调节可能在体内促进乳腺肿瘤的发生,并代表了一种新模型,可用于进一步研究PELP1介导的肿瘤发生的分子机制。 (C)2014 AACR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号